1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
DRIVe EZ-BAA is sponsored by Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation, and Ventures (DRIVe). The DRIVe EZ-BAA provides non-dilutive capital for early and later-stage products in the medical countermeasures space.
BARDA funds companies developing medical countermeasures that address public health and the medical consequences of pandemic influenza and emerging infectious diseases, as well as chemical, biological, radiologic, and nuclear accidents, incidents, and attacks. This covers a broad range of capabilities including drugs and vaccines.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses working on solutions to address health security threats in the United States. Applicants can be from any country, and may include single entities or teams from private sector organizations, government laboratories, and academic institutions. Confirm the full requirements in the official notice before applying.
The current listing shows up to $750,000 over six months (can be extended up to $20M in follow-on funding). Verify award ceilings, matching requirements, and allowable costs in the official notice.
DRIVe EZ-BAA is funded by Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation, and Ventures (DRIVe). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On July 20, 2026, the EDA announced it intends to invest $169 million across six Regional Technology and Innovation Hubs — quantum, nuclear, critical minerals, biosecure manufacturing, pharmaceuticals, and forest bioproducts — after the Trump administration rescinded the Biden-era Phase 2 awards and reran the competition. Only two of the original winners survived. Here is the full breakdown of the six hubs, why four prior awardees were dropped, and what the re-award teaches regional coalitions about competing for the next round.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleAt CGI on September 23, 2026, Global Impact Ventures committed $100 million over three years across economic opportunity, health, education, climate resilience and humanitarian needs. There is no application portal. The access route is the intermediary infrastructure — fiscal sponsorship, grantmaking administration, and a 250-organization network.
Read article